InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR), which is doing business as Canndoc, announced on Tuesday its financial and operating results for the third quarter ended September 30, 2022.
"We continued to execute on our international expansion plans building our footprint organically and exploring strategic acquisitions in key markets to meet the solid demand for our high-quality branded products," Alexander Rabinovitch, the company's CEO, said. "We expect 2022 to be another milestone year for InterCure, solidifying our leadership position in the pharmaceutical cannabis market."
Q3 2022 Financial Highlights
- Record revenue of CA$39 million ($29.4 million), …